Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 760

Sort by

Sort Order Select

Journal Articles

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Blood (2021) 137 (10): 1283–1294.

https://doi.org/10.1182/blood.2019003808

Published: 2021

Journal Articles

Langerhans cell histiocytosis

Carlos Rodriguez-Galindo, Carl E. Allen

Blood (2020) 135 (16): 1319–1331.

https://doi.org/10.1182/blood.2019000934

Published: 2020

Includes: Supplemental data

Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule

Blood (2019) 134 (Supplement_1): 3989.

https://doi.org/10.1182/blood-2019-129829

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Devangi Shah, Jennifer Reichbach Douglas, DNP, APRN, CPHON, Jumana Ashy, Gregory Suhrheinrich, Edward Dela Ziga, MD, Asha B. Pillai, MD, Julio C Barredo, MD, Warren Alperstein, MD

Blood (2019) 134 (Supplement_1): 5680.

https://doi.org/10.1182/blood-2019-125884

Published: 2019

Journal Articles

A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Allison M. Winter, MD, Kirsten M Boughan, DO, Jack Khouri, MD, Paolo Caimi, MD, Faiz Anwer, MD, Brenda Cooper, MD, Deepa Jagadeesh, MDMPH, Robert M. Dean, MD, Aaron T. Gerds, MD MS, Ronald Sobecks, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Marcos de Lima, MD, Navneet S. Majhail, MD MS, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 5705.

https://doi.org/10.1182/blood-2019-124602

Published: 2019

Journal Articles

Outcomes of Autologous Hematopoietic Stem Cell Transplantation Depending on Body-Mass Index in Patients with Multiple Myeloma

Maiia V. Firsova, Larisa P. Mendeleeva, MD PhD Prof, Maxim V. Solovev, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5710.

https://doi.org/10.1182/blood-2019-125808

Published: 2019

Journal Articles

Clinical Outcomes of Ruxolitinib in the Salvage Treatment of Chronic Graft-Versus-Host Disease

Yanping Ji, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Guangyu Sun, Jian Wang, Zimin Sun

Blood (2019) 134 (Supplement_1): 5677.

https://doi.org/10.1182/blood-2019-130138

Published: 2019

Journal Articles

Treatment with Novel Agents in Patients with Multiple Myeloma in México: Data of Characteristics, Treatment Patterns and Outcomes from a Health Care System

Fernando Pérez-Jacobo, MD, Elia Zamora P., MD, Irma Leticia Barrios-Hernández, MD, Nubia Paloma Pérez-Mar, MD, Lidia Mondragón-Posadas, MD, Patricia Galindo-Delgado, MD, Magdalena Bahena-García, MD, Adrian Hernández-López, MD

Blood (2019) 134 (Supplement_1): 5562.

https://doi.org/10.1182/blood-2019-127582

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Elysha Vanderveer, MD BSc, Steven J.T. Huang, BMLSc, Helene Bruyere, MD FCCMG, Tanya Gillan, PhD FCCMG, Charles H. Li, MDFRCPC, Khaled Ramadan, MBBCH, MRCP, FRCPath, Diego Villa, MD MPH, David W. Scott, MBChB, PhD, Kerry J Savage, BSc, MD MSc, Joseph M Connors, MD, Laurie H Sehn, MD, Cynthia L Toze, MD FRCPC, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 4300.

https://doi.org/10.1182/blood-2019-125189

Published: 2019

Journal Articles

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

Waleed Ghanima, MD PhD, Marc Michel, Abderrahim Khelif, Bernadette Darne, Pal André Holme, PhDMD

Blood (2019) 134 (Supplement_1): 2358.

https://doi.org/10.1182/blood-2019-126975

Published: 2019

Journal Articles

Long-Term Outcome of Relapsed Acute T-Lymphoblastic Leukemia (T-ALL) in Children and Adolescents

Luciana Vinti, MD, Luisa Strocchio, MD, Barbara Buldini, MD PhD, Daniela Silvestri, Valentino Conter, MD, Pietro Merli, MD, Carmelo Rizzari, Rosanna Parasole, MD, Maddalena Paganin, PhD, Giuseppe Basso, MD PhD, Marco Zecca, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 2580.

https://doi.org/10.1182/blood-2019-131292

Published: 2019

Journal Articles

Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 2904.

https://doi.org/10.1182/blood-2019-122760

Published: 2019

Journal Articles

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

Rachel Hu, MD, Wei Wei, MS, Kristen Gonter-Aubin, DO, Javier Pinilla Ibarz, MD PhD, Charlene C. Kabel, PharmD, Anthony R. Mato, MDMSCE, Yazan F. Madanat, MD, Sirin Khajavian, MD, Mazyar Shadman, MD, Ashley Hanlon, MD, Danielle M. Brander, MD, Jae H. Park, MD, Martin S. Tallman, MD, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4004.

https://doi.org/10.1182/blood-2019-126381

Published: 2019

Journal Articles

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Sattva S Neelapu, MD, Frederick L. Locke, MD, Nancy L Bartlett, MD, Lazaros J Lekakis, MD, Patrick M Reagan, MD, David B. Miklos, MD PhD, Caron A. Jacobson, MD MMSc, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, Michael Crump, MD, John Kuruvilla, MD, Eric Van Den Neste, MD, Umar Farooq, MD, Lynn Navale, MS, Venita DePuy, PhD, Jenny J. Kim, MD MS, Christian Gisselbrecht, MD

Blood (2019) 134 (Supplement_1): 4095.

https://doi.org/10.1182/blood-2019-125792

Published: 2019

Journal Articles

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, MD Professor, Per-Ola Andersson, MD PhD, Sara Harrysson, MD

Blood (2019) 134 (Supplement_1): 4111.

https://doi.org/10.1182/blood-2019-123785

Published: 2019

Journal Articles

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Ariela Noy, MD, Timothy S. Pardee, MD PhD, Liana Nikolaenko, MD, Raphael Eric Steiner, MD, Jeremy S. Abramson, MD MMSc, Kieron Dunleavy, MD, Sanjeev Luther, MBA

Blood (2019) 134 (Supplement_1): 4087.

https://doi.org/10.1182/blood-2019-131563

Published: 2019

Journal Articles

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Oliver Tomkins, BMBS, MRCP, Joshua Bomsztyk, Helen McCarthy, MBBS, PhD, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, MBBS, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 4016.

https://doi.org/10.1182/blood-2019-129212

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I treat warm autoimmune hemolytic anemia

Langerhans cell histiocytosis

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Outcomes of Autologous Hematopoietic Stem Cell Transplantation Depending on Body-Mass Index in Patients with Multiple Myeloma

Clinical Outcomes of Ruxolitinib in the Salvage Treatment of Chronic Graft-Versus-Host Disease

Treatment with Novel Agents in Patients with Multiple Myeloma in México: Data of Characteristics, Treatment Patterns and Outcomes from a Health Care System

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

Long-Term Outcome of Relapsed Acute T-Lymphoblastic Leukemia (T-ALL) in Children and Adolescents

Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only